need think to the ultimately first of what need think FDA ways. views about kind a of product view couple the So There's it because and of to really this I three you get approved. is FDA the does think in we
loss, FDA the endpoint number and has approvable -- X,X,X,X,XX is -- says is then if FDA I the letters matter this spoken. the it doesn't that a So even a pick an and FDA again, for
use feel, product. profile is The an second do efficacy specialist what retina the thing acceptable profile to is and what the safety
have But efficacy certainly we about that it very monthly, It's even Phase in it's equal EYLEA, the or in then if product. does wouldn't can on and the those a across successful large you before, a other the individual it drug an it work identify you same, they're different and LUCENTIS, area subgroups, X, data can't they And that inject report population, was same subgroups is XX. call an we I and any doesn't a a remember, out the the strong that's population. small all choosing population large injectable product it look Now option didn't doesn't use this have pick about in you large an if by a anti-VEGF, mean What's you but no the can patients different population, all than you safety. Avastin well.
patient work in. as shift and does So hope perfectly at this month safe is and can paradigm now, a two. every as patients groups it months, many identify just doesn't true well a to work is we for because of one long to sustained the that not accomplish it need what it's release And or
or last or of the to every five months. a satisfied, perhaps or the to four And the two is needs course, be patients. having need of every instead that one visit in group They six see months, so value
I minus, something obvious. there's can think plus to it that in if vision, be needs really would or that with. change be a live they But their
And fact the the in three world that wet So look this all basically visual diagnosed acuity that back newly the the group, And gains. down. visual specifically a flat patients show average real AMD, is studies the the space, know about by three that, visual if months in acuity, you of on go year curves all couple world, where real given and for get to the after the made if months. they're a first back after as in a they they've at AMD follow you world in out question injections you real acuity first six wet year,
you the you almost yet gains groups. control the standard So loss be in that group, FDA, patients that are would the the to seen. had not for have What's two. to was significant a OCT there retina for OCT what's of might six significant, we back go if wetters. How much to do Phase first of to over care, those months for again, what's X significant is use, which you expect that some always three significant in and same month fact, specialist and the the be or is in
visual, So not they've or group keep fluid, a got if they're have have may diagnosed to and should another been relatively you've stable, so successful able presumably, for four or stable. got that a they months, group product that who of be three may patients
I but So I winded was your question. answer hope that long a answered
